NeuroPace Shares Plummet Amid SEC Filings and Trials
By ATTN Desk · Editorial oversight: Sean Han
NeuroPace Inc. (NASDAQ: NPCE)
NeuroPace Inc. is a commercial-stage medical device company headquartered in Mountain View, California. Its primary offering, the RNS® System, is an implantable, brain-responsive neurostimulation platform designed to treat adults with drug-resistant focal epilepsy. Approved by the U.S. Food and Drug Administration, the RNS System delivers therapy directly at the seizure focus and records intracranial electroencephalography (iEEG) data to assist physicians in optimizing treatment plans.
Corporate Structure and Workforce
- Founded: 1999
- Headquarters: 455 N. Bernardo Avenue, Mountain View, CA 94043
- Employees: 51 – 200 (LinkedIn estimate)
- Key Roles:
- Engineering and R&D teams developing device hardware and software
- Clinical and medical affairs professionals supporting trial design and physician education
- Regulatory, legal, and quality functions ensuring compliance with FDA requirements
- Commercial and therapy consultants engaging epilepsy centers and healthcare providers
Developments and News
Stock Performance (as of 2025-05-27)
- Share Price: $11.5287
- Daily Change: – 34.79%
- Volume: 186,704 shares
- Exchange: NASDAQ (NPCE)
SEC Filings
- Form 8-K (2025-05-27): Disclosed Items 7.01, 8.01 and 9.01, covering Regulation FD updates and operational events.
- Schedule 13G/A (2025-05-15): OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC reported beneficial ownership of 3,406,335 shares (10.5% of common stock) as of March 31, 2025.
- Schedule 13G (2025-05-15): Polar Capital Holdings Plc and Polar Capital LLP reported joint ownership of 2,972,003 shares (9.13% of common stock) as of March 31, 2025.
Clinical Trial Programs
- NAUTILUS Study: FDA-approved IDE trial of bilateral thalamic responsive stimulation in drug-resistant idiopathic generalized epilepsy (ages ≥ 12).
- LGS Study: Pilot trial of thalamocortical responsive stimulation in Lennox-Gastaut Syndrome (ages ≥ 12).
- RESPONSE Study: Pivotal investigation of RNS in adolescents (ages 12 – 17) with focal seizures localized to ≤ 2 foci.
Media Features
- Coverage in The New York Times, USA Today, NPR, and Fox News regarding patient experiences related to seizure reduction and quality of life.
- Reports covering first-in-human experiences and patient testimonials from various U.S. centers.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Market Capitalization (intraday) | $373.6 million |
| Revenue (TTM) | $84.31 million |
| Net Income (TTM) | – $24.8 million |
| Profit Margin | – 29.42% |
| Diluted EPS (TTM) | – $0.82 |
| Total Cash (MRQ) | $66.26 million |
| Total Debt/Equity (MRQ) | 301.42% |
| Price/Sales (TTM) | 6.28× |
| Price/Book (MRQ) | 23.89× |
| Beta (5Y Monthly) | 2.05 |
- Cash Runway: With $66 million in cash against negative free cash flow, the company’s funding is necessary for ongoing R&D and trial operations.
- Leverage: High debt/equity ratio (301%) indicates prior financing terms; further refinancing or equity raises may be necessary.
- Revenue Trends: Increases in RNS System placements drive quarterly revenue growth, although profitability is targeted over the longer term.
- Strategic Focus: Expanding RNS indications into generalized epilepsy (NAUTILUS) and pediatric focal epilepsy (RESPONSE) aims to broaden the market.
Market Position and Industry Context
- Epilepsy Prevalence: Approximately 3.5 million Americans experience epilepsy, with roughly 30% of cases being refractory to anti-seizure medications.
- Competitive Landscape:
- Vagus nerve stimulation (VNS) and deep brain stimulation (DBS) systems
- Emerging non-invasive neuromodulation technologies
- Differentiator: The RNS System is the first FDA-approved implantable device that continuously monitors iEEG, delivers responsive therapy in real-time, and stores data for physician review.
- Availability: The RNS System is provided at most Comprehensive Epilepsy Centers (CECs) in the U.S., supported by physician training and established reimbursement pathways.
tl;dr
- NPCE shares closed at $11.5287 on 2025-05-27, down 34.79% on 186,704 shares traded.
- Form 8-K filed on 2025-05-27 disclosed key operational and financial information.
- OrbiMed reported a 10.5% stake, and Polar Capital holds 9.13%, both as of March 31, 2025.
- Ongoing IDE trials (NAUTILUS, LGS, RESPONSE) aim to extend RNS applications to generalized and pediatric epilepsy.
- Quarterly revenue growth supports trial and commercial expansion; future performance is tied to enrollment milestones and upcoming quarterly results (earnings window: August 11–15, 2025).